Acquired somatic mutations in the Janus kinase 2 (JAK2) and thrombopoietin receptor (MPL) genes have been described as major contributors to the pathogenesis and clinical characteristics of myeloproliferative neoplasms (MPN). 1 Among these, the G4T single nucleotide transversion in exon 14 of JAK2 (JAK2-V617F) is the most frequent in MPN. 1 Point mutations and deletions in exon 12 of the JAK2 gene are the most common genetic aberrations associated with JAK2-V617F-negative polycythemia vera. 2, 3 Despite numerous investigations on the impact of JAK2 mutations on MPN phenotype, the genetic mechanisms facilitating the somatic acquisition of JAK2-V617F and its influence on phenotypic variation among the three main MPN entities remain unclear.
Bone marrow transplant models have shown that the expression of JAK2-V617F in murine bone marrow hematopoietic cells induces phenotypic features resembling human MPN. 4, 5 Most interestingly, JAK2-V617F-transformed Balb/c and C57Bl/6 mice exhibited strain-specific differences in JAK2-V617F-associated disease phenotype. 5 This finding gave rise to the hypothesis that individual genetic variation influences the clinical manifestation of JAK2-V617F-positive MPN and provided a first clue as to how a single point mutation in the JAK2 gene can constitute three distinct clinical MPN entities. To examine the contribution of interindividual genetic differences on MPN disease phenotypes, Pardanani et al. studied genetic variation in the erythropoietin receptor (EPOR), granulocyte colony-stimulating factor receptor (GCSFR), MPL as well as in the JAK2 gene. 3 In a cohort of 179 MPN patients, an intragenic JAK2 haplotype showed significant association with the diagnosis of polycythemia vera, but not essential thrombocythemia (ET) or primary myelofibrosis (PMF) (Figure 1) .
Two independent studies have recently offered further insights into the effect of hereditary factors on the pathogenesis of MPN. 6, 7 Genotyping single-nucleotide polymorphisms in MPN patients with uniparental disomy on chromosome 9p revealed a haplotype that includes the JAK2 gene and predisposes to the development of JAK2-V617F-positive MPN. 7 In a study addressing the incidence of multiple acquisitions of the JAK2-V617F mutation, 6 we obtained evidence that JAK2-V617F is preferentially acquired on one of the two common JAK2 haplotypes, which we refer to as the GGCC haplotype ( Figure 1 ). A total of 88% of all JAK2-V617F mutations were acquired on the chromosome carrying the GGCC haplotype of JAK2. Association analysis showed that MPN patients heterozygous or homozygous for the GGCC haplotype were at higher risk of acquiring the JAK2-V617F mutation. The same conclusions were reached in an independent study with a single-nucleotide polymorphism . The JAK2 exon 12 mutation locus and the SNP used for association analysis in this study (rs10974944) are depicted. Exon 14 and the locus of the JAK2-V617F mutation is shown with the SNP in intron 14 (rs12343867) used for the earlier association study. 6 located in the intron 12 of the JAK2 gene, which is contained in the GGCC haplotype and was confirmed to be significantly associated with JAK2-V617F-positive MPN. 8 One interpretation of these data is that the GGCC haplotype of JAK2 is more susceptible to DNA repair defects or replication infidelity and, therefore, is more likely to acquire somatic mutations such as JAK2-V617F. To further explore the hypothesis of differential mutability as a haplotype property, we investigated whether somatic mutagenesis on the GGCC haplotype is restricted to the JAK2-V617F mutation site or involves a larger genomic region. To determine the haplotype preference of other acquired mutations of JAK2, we tested whether the various JAK2 exon 12 mutations also preferentially arise on the GGCC haplotype. We examined a cohort of 44 Caucasian polycythemia vera patients of Western European descent who were positive for JAK2 exon 12 mutations (Table 1) . We genotyped all patients for a tagging single-nucleotide polymorphism in intron 12 of the JAK2 gene (rs10974944), that is in linkage disequilibrium with the GGCC haplotype. 6 Association analysis revealed a significant correlation between the occurrence of JAK2 exon 12 mutations and the GGCC haplotype when compared with an Austrian non-MPN control population (n ¼ 290; Table 2 , Figure 1 ). According to allelic association analysis, patients carrying the G variant of rs10974944 were at higher risk of acquiring a point mutation or deletion in exon 12 of JAK2 (P ¼ 0.0016; OR (odds ratio) ¼ 2.10; 95% CI (confidence interval) ¼ 1.31-3.35). About 64 percent of all JAK2 exon 12 mutation-positive patients carried the GGCC haplotype in a heterozygous or homozygous state. The minor allele frequencies did not differ significantly in the Austrian non-MPN control cohort and in the publicly available genotype data of the Caucasian HapMap CEU and TSI populations (0.24, 0.25 and 0.30, respectively), excluding the influence of population-specific differences in allelic distribution on the computed association analysis. Our data provide evidence that the increased susceptibility to somatic mutagenesis exhibited by the JAK2 GGCC haplotype is not restricted to JAK2-V617F, but also includes the less frequent but more diverse JAK2 exon 12 mutations.
There are two alternative hypotheses that could explain the observed associations: (i) JAK2 mutations occur randomly on both haplotypes, but the GGCC haplotype holds certain features necessary to propagate MPN disease phenotype, or (ii) the GGCC haplotype is more susceptible to somatic mutagenesis and therefore the V617F mutation and exon 12 mutations of the JAK2 gene preferentially arise on this particular DNA sequence variant. Several possible mechanisms have been suggested to influence the disease susceptibility through haplotype variants. Yet, 'differential mutability', as a hypothetical haplotype property, has not been considered in investigations of cancer susceptibilities so far. Our data suggest that a certain combination of single-nucleotide polymorphism variants can influence genetic repair or replication mechanisms leading to a higher susceptibility and accumulation of defects at that particular genomic region. We still cannot exclude the possibility that the described haplotype is in linkage with a yet unidentified functional variant, and thereby influences disease manifestation Table 1 List of JAK2 exon 12 mutation-positive PV cases Location ID JAK2 exon 12 mutation
Abbreviations: JAK2, janus kinase 2; PV, polycythemia vera. An important mechanism of action of allogeneic hematopoietic cell transplantation (HCT) is the graft versus leukemia (GVL) effect, and in non-myeloablative conditioning transplantation this immune-mediated effect is the only curative principle. 1 It has been clearly shown that T-cell responses are the main effector mechanisms of the GVL reactions, 2 and in HLAidentical donor-recipient transplantations individual targets recognized by T cells in the graft have been characterized as proteins or protein fragments that are not expressed in the donor, and thus represent neo-antigens to the transferred T cells. mHags may be encoded on the Y chromosome (in sex-mismatched HCT) 3 or be derived from polymorphismsFthat is, singlenucleotide polymorphisms (SNP) that are disparate between donor and recipient. 4 The HER2 protein is a well-characterized tumor-associated antigen (TAA), which is overexpressed in many solid cancers. 5 Limited data are available regarding the expression in hematological malignancies; 6 however, by intracellular staining of 14 acute myeloid leukemia (AML) samples, we could show that two of them expressed HER2 (Figure 1a) . HER2 comprise five non-synonymous SNPs, two of which have a frequency close to 0.5 (positions 1140 and 1170; http://www.genome.utah.edu/genesnps/). By allele-specific RT-PCR for the 1170 SNP of a panel of tumor cell lines, we detected quite frequent homozygous expression, supporting the 1/1 allelic distribution (Figure 1b) . By using the SNEP database, 7 we identified a peptide from the 1170 A (GCC)-P (CCC) polymorphism, which potentially would bind to HLA-A2. By analyzing the actual binding of the peptides through the assembly assay, we showed that the peptides did indeed bind to HLA-A2, although with low affinity (data not shown). We used peptide-loaded dendritic cell (DC) from a homozygous A/A donor to stimulate autologous peripheral blood mononuclear cell (PBMC) for cloning and establishment of a cytotoxic T lymphocyte (CTL) clone specific for the HER2_P peptide as described earlier. 8 This clone (HER2_P#3) was used to show specific cytotoxic activity against the HER2_P peptide loaded to T2 cells, and importantly, absence of recognition of the HER2_A peptide (Figure 2a) . The HLA restriction of the killing was shown by blocking by the HLA class I specific antibody W6/32
